Maternal embryonic leucine zipper kinase (MELK) as a promising therapeutic target in triple negative breast cancer
10.2174/0118715206389899250522091159 · doi-reference
MELK/MPK38 in cancer: from mechanistic aspects to therapeutic strategies
10.1016/j.drudis.2020.09.029 · doi-reference
Discovery of juglone derivatives as novel STAT3 inhibitors with potent suppression of cancer cell stemness against breast cancer
10.1021/acs.jmedchem.5c01301 · doi-reference
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients
10.1002/gcc.23014 · doi-reference
Emerging trends and research foci of epithelial–mesenchymal transition in gliomas: A scientometric analysis and review
10.3389/fonc.2022.1015236 · doi-reference
The complex path from mammary ductal hyperplasia to breast cancer: Elevated Malignancy risk in atypical forms
10.3390/biomedicines14020349 · doi-reference
Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway
10.1007/s00221-023-06693-8 · doi-reference
Targeting MELK in tumor cells and tumor microenvironment: from function and mechanism to therapeutic application
10.1007/s12094-024-03664-5 · doi-reference
Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces
10.20517/cdr.2022.20 · doi-reference
Maternal embryonic leucine zipper kinase (MELK), a potential therapeutic target for neuroblastoma
10.1158/1535-7163.mct-18-0819 · doi-reference
High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo
10.3802/jgo.2020.31.e93 · doi-reference
Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase
10.1042/bcj20160792 · doi-reference
Maternal embryonic leucine zipper kinase (MELK) in cancer: Biological functions, therapeutic potential, and controversies
10.3390/biology15020200 · doi-reference
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy
10.1186/s12943-024-02049-0 · doi-reference
A conditional dependency on MELK for the proliferation of triple-negative breast cancer cells
10.1016/j.isci.2018.10.015 · doi-reference
MELK expression correlates with tumor mitotic activity but is not required for cancer growth
10.7554/elife.32838 · doi-reference
Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia
10.1038/s41388-018-0333-x · doi-reference
Targeting MELK improves PD-1 blockade efficiency in cervical cancer via enhancing antitumor immunity
10.1016/j.omton.2024.200759 · doi-reference
Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer
10.1038/s41598-024-59001-x · doi-reference
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
10.1186/s13046-022-02464-5 · doi-reference
Discovery of first-in-class PROTACs targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of Burkitt lymphoma
10.1039/d4md00252k · doi-reference
Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression
10.1158/1535-7163.mct-08-0188 · doi-reference
The transcription factor FOXM1 is a cellular target of the natural product thiostrepton
10.1038/nchem.1114 · doi-reference
Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells
10.1371/journal.pone.0005592 · doi-reference
Phillygenin, a MELK inhibitor, inhibits cell survival and epithelial–mesenchymal transition in pancreatic cancer cells
10.2147/ott.s238958 · doi-reference
Corosolic acid induces cell cycle arrest and cell apoptosis in human retinoblastoma Y-79 cells via disruption of MELK-FoxM1 signaling
10.3892/or.2018.6339 · doi-reference
MELK is not necessary for the proliferation of basal-like breast cancer cells
10.7554/elife.26693 · doi-reference
Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies
10.1038/s41419-020-03344-6 · doi-reference
Toward the validation of maternal embryonic leucine zipper kinase: Discovery, optimization of highly potent and selective inhibitors, and preliminary biology insight
10.1021/acs.jmedchem.6b00052 · doi-reference
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials
10.7554/elife.24179 · doi-reference
OTSSP167 abrogates mitotic checkpoint through inhibiting multiple mitotic kinases
10.1371/journal.pone.0153518 · doi-reference
MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells
10.1016/j.ygyno.2017.02.016 · doi-reference
MELK is a novel therapeutic target in high-risk neuroblastoma
10.18632/oncotarget.23515 · doi-reference
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia
10.18632/oncotarget.2642 · doi-reference
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor
10.18632/oncotarget.7685 · doi-reference
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer
10.18632/oncotarget.790 · doi-reference
MELK is a prognostic biomarker and correlated with immune infiltration in glioma
10.3389/fneur.2022.977180 · doi-reference
Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner
10.1002/stem.1322 · doi-reference
The roles of TOPK in tumorigenesis and development: Structure, mechanisms, pathways, and therapeutic implications
10.7150/ijbs.122960 · doi-reference
Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway
10.1093/neuonc/nor023 · doi-reference
